DOI: 10.1016/s0149-2918(04)80001-8. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

10.1016/s0149-2918(04)80001-8

Crossref journal-article

Elsevier BV

Clinical Therapeutics (78)

Bibliography

Mattoes, H. M., Kuti, J. L., Drusano, G. L., & Nicolau, D. P. (2004). Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clinical Therapeutics, 26(8), 1187â1198.

Authors 4

Holly M. Mattoes (first)
Joseph L. Kuti (additional)
George L. Drusano (additional)
David P. Nicolau (additional)

References 52 Referenced 93

{'key': '10.1016/S0149-2918(04)80001-8_bib1', 'first-page': '229', 'article-title': 'Prescribing guidelines for severe Pseudomonas infections', 'volume': '49', 'author': 'Giamarellou', 'year': '2002'} / Prescribing guidelines for severe Pseudomonas infections by Giamarellou (2002)
10.1093/jac/46.suppl_2.1 / J Antimicrob Chemother / Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility by Jones (2000)
10.2165/00003088-200039030-00002 / Clin Pharmacokinet / Comparative pharmacokinetics of the carbapenems: Clinical implications by Mouton (2000)
10.1016/S0732-8893(03)00112-3 / Diagn Microbiol Infect Dis / Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America by Rhomberg (2003)
10.1179/joc.2001.13.4.363 / J Chemother / In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains by Jones (2001)
10.2165/00003088-199528040-00002 / Clin Pharmacokinet / Meropenem clinical pharmacokinetics by Mouton (1995)
10.1128/AAC.47.4.1439-1442.2003 / Antimicrob Agents Chemother / Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers by Laethem (2003)
10.1378/chest.115.2.462 / Chest / Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients by Kollef (1999)
{'key': '10.1016/S0149-2918(04)80001-8_bib9', 'series-title': 'A randomized trial', 'first-page': '621', 'article-title': 'Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia', 'volume': '132', 'author': 'Fagon', 'year': '2000'} / A randomized trial / Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia by Fagon (2000)
10.1097/01.CCM.0000098031.24329.10 / Crit Care Med / Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis by Garnacho-Montero (2003)
10.1086/344653 / Clin Infect Dis / Prevention of resistance: A goal for dose selection of antimicrobial agents by Drusano (2003)
10.2165/00019053-200220080-00002 / PharmacoEconomics / Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance by Kuti (2002)
10.1086/516284 / Clin Infect Dis / Pharmacokinetic/pharmacodynamic parameters: Rationale for antimicrobial dosing of mice and men by Craig (1998)
10.1093/jac/39.6.677 / J Antimicrob Chemother / Once-daily dosing of aminoglycosides: Review and recommendations for clinical practice by Freeman (1997)
10.1128/AAC.36.12.2577 / Antimicrob Agents Chemother / Continuous infusion of β-lactam antibiotics by Craig (1992)
10.1172/JCI200316814 / J Clin Invest / Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy by Jumbe (2003)
10.1093/infdis/155.1.93 / J Infect Dis / Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration by Moore (1987)
10.1093/jac/46.5.669 / J Antimicrob Chemother / Application of fluoroquinolone pharmacodynamics by Wright (2000)
10.1001/jama.279.2.125 / JAMA / Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials by Preston (1998)
10.1128/AAC.43.3.672 / Antimicrob Agents Chemother / Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection by Lacy (1999)
10.1128/AAC.43.7.1549 / Antimicrob Agents Chemother / Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity by Rybak (1999)
10.1086/514622 / Clin Infect Dis / The pharmacodynamics of beta-lactams by Turnidge (1998)
10.1128/AAC.26.5.678 / Antimicrob Agents Chemother / Postantibiotic effect of imipenem on Pseudomonas aeruginosa by Bustamente (1984)
{'key': '10.1016/S0149-2918(04)80001-8_bib24', 'first-page': '265', 'article-title': 'Role of pharmacodynamics in designing dosage regimens for β-lactams', 'volume': '67', 'author': 'Kotapati', 'year': '2003', 'journal-title': 'Conn Med'} / Conn Med / Role of pharmacodynamics in designing dosage regimens for β-lactams by Kotapati (2003)
{'key': '10.1016/S0149-2918(04)80001-8_bib25', 'series-title': 'Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy', 'first-page': '36', 'article-title': 'Pharmacodynamic evaluation of extending the infusion time of piperacillin/tazobactam doses using Monte Carlo analysis', 'author': 'Lomaestro', 'year': '2001'} / Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy / Pharmacodynamic evaluation of extending the infusion time of piperacillin/tazobactam doses using Monte Carlo analysis by Lomaestro (2001)
10.1128/AAC.45.1.13-22.2001 / Antimicrob Agents Chemother / Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint by Drusano (2001)
10.1016/S0732-8893(00)00185-1 / Diagn Microbiol Infect Dis / The use of Monte Carlo simulation to examine pharmacodynamic variances of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumoniae by Ambrose (2000)
10.1086/383320 / J Infect Dis / Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia by Drusano (2004)
{'key': '10.1016/S0149-2918(04)80001-8_bib29', 'series-title': 'Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy', 'first-page': '9', 'article-title': 'Use of pharmacodynamic principles and stochastic modeling to choose an optimal empiric cefepime dose for suspected Pseudomonas aeruginosa infections within a single institution', 'author': 'Paterson', 'year': '2002'} / Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy / Use of pharmacodynamic principles and stochastic modeling to choose an optimal empiric cefepime dose for suspected Pseudomonas aeruginosa infections within a single institution by Paterson (2002)
10.1016/S0924-8579(01)00474-5 / Int J Antimicrob Agents / Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients by Kitzes-Cohen (2002)
{'key': '10.1016/S0149-2918(04)80001-8_bib31', 'series-title': 'Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy', 'first-page': '2', 'article-title': 'Evaluation of pharmacodynamic target attainment between healthy subject and patient data using Monte Carlo simulation', 'author': 'Kuti', 'year': '2003'} / Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy / Evaluation of pharmacodynamic target attainment between healthy subject and patient data using Monte Carlo simulation by Kuti (2003)
10.1093/ajhp/60.6.565 / Am J Health Syst Pharm / Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts by Kuti (2003)
10.1093/ajhp/61.12.1264 / Am J Health Syst Pharm / Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts in a large teaching hospital by Kotapati (2004)
10.1592/phco.24.1.8.34804 / Pharmacotherapy / Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae Acinetobacter baumannii, and Pseudomonas aeruginosa by Kuti (2004)
{'key': '10.1016/S0149-2918(04)80001-8_bib35', 'first-page': '24', 'article-title': 'The treatment of pulmonary infection in cystic fibrosis', 'volume': '96', 'author': 'Webb', 'year': '1995', 'journal-title': 'Scand J Infect Dis'} / Scand J Infect Dis / The treatment of pulmonary infection in cystic fibrosis by Webb (1995)
10.1007/BF02914541 / Clin Rev Allergy / Pharmacokinetics of drugs in cystic fibrosis by Spino (1991)
10.1007/s100960050211 / Eur J Clin Microbiol Infect Dis / Pharmacokinetics of meropenem in patients with cystic fibrosis by Christensson (1998)
10.1159/000063216 / Chemotherapy / Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients by Bui (2001)
10.1592/phco.23.8.988.32878 / Pharmacotherapy / Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion by Dandekar (2003)
10.1093/jac/dkg378 / J Antimicrob Chemother / Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection by Jaruratanasirikul (2003)
{'key': '10.1016/S0149-2918(04)80001-8_bib41', 'series-title': 'Program and Abstracts of the International Conference of the American Thoracic Society', 'article-title': 'Prevention of emergence of resistance in Pseudomonas aeruginosa infections through pharmacodynamic dosing and combination chemotherapy', 'author': 'Drusano', 'year': '2002'} / Program and Abstracts of the International Conference of the American Thoracic Society / Prevention of emergence of resistance in Pseudomonas aeruginosa infections through pharmacodynamic dosing and combination chemotherapy by Drusano (2002)
10.1177/0091270003257225 / J Clin Pharmacol / Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem by Kuti (2003)
Kuti JL, Moss KM, Nicolau DP, et al. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a cystic fibrosis patient by applying pharmacodynamic concepts to meropenem therapy. Pharmacotherapy. In press.
10.1016/0002-9343(79)90242-0 / Am J Med / A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients by Bodey (1979)
10.2165/00003088-199835050-00004 / Clin Pharmacokinet / Continuous infusion of β-lactam antibiotics by MacGowan (1998)
10.1592/phco.22.7.471.33665 / Pharmacotherapy / Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital by Grant (2002)
{'key': '10.1016/S0149-2918(04)80001-8_bib47', 'first-page': '156', 'article-title': 'Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride', 'volume': '51', 'author': 'Walker', 'year': '1998', 'journal-title': 'Can J Hosp Pharm'} / Can J Hosp Pharm / Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride by Walker (1998)
10.1093/ajhp/54.4.412 / Am J Health Syst Pharm / Stability of meropenem in intravenous solutions by Patel (1997)
10.1093/ajhp/57.10.992 / Am J Health Syst Pharm / Stability of meropenem in a portable infusion device in a cold pouch by Grant (2000)
10.1093/jac/28.6.911 / J Antimicrob Chemother / Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion by Mouton (1991)
10.1093/jac/43.4.523 / J Antimicrob Chemother / Continuous infusion versus intermittent administration of meropenem in critically ill patients by Thalhammer (1999)
10.1016/S0149-2918(04)90051-3 / Clin Ther / Pharmacokinetic properties and stability of continuousinfusion meropenem in adults with cystic fibrosis by Kuti (2004)

Dates

Type	When
Created	20 years, 10 months ago (Oct. 14, 2004, 11:18 a.m.)
Deposited	2 years, 4 months ago (April 29, 2023, 11:31 a.m.)
Indexed	2 months, 4 weeks ago (June 4, 2025, 6:05 a.m.)
Issued	21 years, 1 month ago (Aug. 1, 2004)
Published	21 years, 1 month ago (Aug. 1, 2004)
Published Print	21 years, 1 month ago (Aug. 1, 2004)

Funders 0

None

BibTeX

@article{Mattoes_2004, title={Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem}, volume={26}, ISSN={0149-2918}, url={http://dx.doi.org/10.1016/s0149-2918(04)80001-8}, DOI={10.1016/s0149-2918(04)80001-8}, number={8}, journal={Clinical Therapeutics}, publisher={Elsevier BV}, author={Mattoes, Holly M. and Kuti, Joseph L. and Drusano, George L. and Nicolau, David P.}, year={2004}, month=aug, pages={1187–1198} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        6,
        4
      ]
    ],
    "date-time": "2025-06-04T10:05:51Z",
    "timestamp": 1749031551627
  },
  "reference-count": 52,
  "publisher": "Elsevier BV",
  "issue": "8",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2004,
            8,
            1
          ]
        ],
        "date-time": "2004-08-01T00:00:00Z",
        "timestamp": 1091318400000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://www.elsevier.com/tdm/userlicense/1.0/"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2004,
        8
      ]
    ]
  },
  "DOI": "10.1016/s0149-2918(04)80001-8",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2004,
        10,
        14
      ]
    ],
    "date-time": "2004-10-14T15:18:48Z",
    "timestamp": 1097767128000
  },
  "page": "1187-1198",
  "source": "Crossref",
  "is-referenced-by-count": 93,
  "title": "Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem",
  "prefix": "10.1016",
  "volume": "26",
  "author": [
    {
      "given": "Holly M.",
      "family": "Mattoes",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Joseph L.",
      "family": "Kuti",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "George L.",
      "family": "Drusano",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "David P.",
      "family": "Nicolau",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "78",
  "reference": [
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib1",
      "first-page": "229",
      "article-title": "Prescribing guidelines for severe Pseudomonas infections",
      "volume": "49",
      "author": "Giamarellou",
      "year": "2002"
    },
    {
      "issue": "Suppl B",
      "key": "10.1016/S0149-2918(04)80001-8_bib2",
      "doi-asserted-by": "crossref",
      "first-page": "1",
      "DOI": "10.1093/jac/46.suppl_2.1",
      "article-title": "Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility",
      "volume": "46",
      "author": "Jones",
      "year": "2000",
      "journal-title": "J Antimicrob Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib3",
      "doi-asserted-by": "crossref",
      "first-page": "185",
      "DOI": "10.2165/00003088-200039030-00002",
      "article-title": "Comparative pharmacokinetics of the carbapenems: Clinical implications",
      "volume": "39",
      "author": "Mouton",
      "year": "2000",
      "journal-title": "Clin Pharmacokinet"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib4",
      "doi-asserted-by": "crossref",
      "first-page": "365",
      "DOI": "10.1016/S0732-8893(03)00112-3",
      "article-title": "Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America",
      "volume": "47",
      "author": "Rhomberg",
      "year": "2003",
      "journal-title": "Diagn Microbiol Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib5",
      "doi-asserted-by": "crossref",
      "first-page": "363",
      "DOI": "10.1179/joc.2001.13.4.363",
      "article-title": "In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains",
      "volume": "13",
      "author": "Jones",
      "year": "2001",
      "journal-title": "J Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib6",
      "doi-asserted-by": "crossref",
      "first-page": "275",
      "DOI": "10.2165/00003088-199528040-00002",
      "article-title": "Meropenem clinical pharmacokinetics",
      "volume": "28",
      "author": "Mouton",
      "year": "1995",
      "journal-title": "Clin Pharmacokinet"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib7",
      "doi-asserted-by": "crossref",
      "first-page": "1439",
      "DOI": "10.1128/AAC.47.4.1439-1442.2003",
      "article-title": "Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers",
      "volume": "47",
      "author": "Laethem",
      "year": "2003",
      "journal-title": "Antimicrob Agents Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib8",
      "doi-asserted-by": "crossref",
      "first-page": "462",
      "DOI": "10.1378/chest.115.2.462",
      "article-title": "Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients",
      "volume": "115",
      "author": "Kollef",
      "year": "1999",
      "journal-title": "Chest"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib9",
      "series-title": "A randomized trial",
      "first-page": "621",
      "article-title": "Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia",
      "volume": "132",
      "author": "Fagon",
      "year": "2000"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib10",
      "doi-asserted-by": "crossref",
      "first-page": "2742",
      "DOI": "10.1097/01.CCM.0000098031.24329.10",
      "article-title": "Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis",
      "volume": "31",
      "author": "Garnacho-Montero",
      "year": "2003",
      "journal-title": "Crit Care Med"
    },
    {
      "issue": "Suppl 1",
      "key": "10.1016/S0149-2918(04)80001-8_bib11",
      "doi-asserted-by": "crossref",
      "first-page": "S42",
      "DOI": "10.1086/344653",
      "article-title": "Prevention of resistance: A goal for dose selection of antimicrobial agents",
      "volume": "36",
      "author": "Drusano",
      "year": "2003",
      "journal-title": "Clin Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib12",
      "doi-asserted-by": "crossref",
      "first-page": "513",
      "DOI": "10.2165/00019053-200220080-00002",
      "article-title": "Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance",
      "volume": "20",
      "author": "Kuti",
      "year": "2002",
      "journal-title": "PharmacoEconomics"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib13",
      "doi-asserted-by": "crossref",
      "first-page": "1",
      "DOI": "10.1086/516284",
      "article-title": "Pharmacokinetic/pharmacodynamic parameters: Rationale for antimicrobial dosing of mice and men",
      "volume": "26",
      "author": "Craig",
      "year": "1998",
      "journal-title": "Clin Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib14",
      "doi-asserted-by": "crossref",
      "first-page": "677",
      "DOI": "10.1093/jac/39.6.677",
      "article-title": "Once-daily dosing of aminoglycosides: Review and recommendations for clinical practice",
      "volume": "39",
      "author": "Freeman",
      "year": "1997",
      "journal-title": "J Antimicrob Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib15",
      "doi-asserted-by": "crossref",
      "first-page": "2577",
      "DOI": "10.1128/AAC.36.12.2577",
      "article-title": "Continuous infusion of \u03b2-lactam antibiotics",
      "volume": "36",
      "author": "Craig",
      "year": "1992",
      "journal-title": "Antimicrob Agents Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib16",
      "doi-asserted-by": "crossref",
      "first-page": "275",
      "DOI": "10.1172/JCI200316814",
      "article-title": "Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy",
      "volume": "112",
      "author": "Jumbe",
      "year": "2003",
      "journal-title": "J Clin Invest"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib17",
      "doi-asserted-by": "crossref",
      "first-page": "93",
      "DOI": "10.1093/infdis/155.1.93",
      "article-title": "Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration",
      "volume": "155",
      "author": "Moore",
      "year": "1987",
      "journal-title": "J Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib18",
      "doi-asserted-by": "crossref",
      "first-page": "669",
      "DOI": "10.1093/jac/46.5.669",
      "article-title": "Application of fluoroquinolone pharmacodynamics",
      "volume": "46",
      "author": "Wright",
      "year": "2000",
      "journal-title": "J Antimicrob Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib19",
      "doi-asserted-by": "crossref",
      "first-page": "125",
      "DOI": "10.1001/jama.279.2.125",
      "article-title": "Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials",
      "volume": "279",
      "author": "Preston",
      "year": "1998",
      "journal-title": "JAMA"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib20",
      "doi-asserted-by": "crossref",
      "first-page": "672",
      "DOI": "10.1128/AAC.43.3.672",
      "article-title": "Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection",
      "volume": "43",
      "author": "Lacy",
      "year": "1999",
      "journal-title": "Antimicrob Agents Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib21",
      "doi-asserted-by": "crossref",
      "first-page": "1549",
      "DOI": "10.1128/AAC.43.7.1549",
      "article-title": "Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity",
      "volume": "43",
      "author": "Rybak",
      "year": "1999",
      "journal-title": "Antimicrob Agents Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib22",
      "doi-asserted-by": "crossref",
      "first-page": "10",
      "DOI": "10.1086/514622",
      "article-title": "The pharmacodynamics of beta-lactams",
      "volume": "27",
      "author": "Turnidge",
      "year": "1998",
      "journal-title": "Clin Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib23",
      "doi-asserted-by": "crossref",
      "first-page": "678",
      "DOI": "10.1128/AAC.26.5.678",
      "article-title": "Postantibiotic effect of imipenem on Pseudomonas aeruginosa",
      "volume": "26",
      "author": "Bustamente",
      "year": "1984",
      "journal-title": "Antimicrob Agents Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib24",
      "first-page": "265",
      "article-title": "Role of pharmacodynamics in designing dosage regimens for \u03b2-lactams",
      "volume": "67",
      "author": "Kotapati",
      "year": "2003",
      "journal-title": "Conn Med"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib25",
      "series-title": "Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy",
      "first-page": "36",
      "article-title": "Pharmacodynamic evaluation of extending the infusion time of piperacillin/tazobactam doses using Monte Carlo analysis",
      "author": "Lomaestro",
      "year": "2001"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib26",
      "doi-asserted-by": "crossref",
      "first-page": "13",
      "DOI": "10.1128/AAC.45.1.13-22.2001",
      "article-title": "Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint",
      "volume": "45",
      "author": "Drusano",
      "year": "2001",
      "journal-title": "Antimicrob Agents Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib27",
      "doi-asserted-by": "crossref",
      "first-page": "151",
      "DOI": "10.1016/S0732-8893(00)00185-1",
      "article-title": "The use of Monte Carlo simulation to examine pharmacodynamic variances of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumoniae",
      "volume": "38",
      "author": "Ambrose",
      "year": "2000",
      "journal-title": "Diagn Microbiol Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib28",
      "doi-asserted-by": "crossref",
      "first-page": "1590",
      "DOI": "10.1086/383320",
      "article-title": "Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia",
      "volume": "189",
      "author": "Drusano",
      "year": "2004",
      "journal-title": "J Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib29",
      "series-title": "Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy",
      "first-page": "9",
      "article-title": "Use of pharmacodynamic principles and stochastic modeling to choose an optimal empiric cefepime dose for suspected Pseudomonas aeruginosa infections within a single institution",
      "author": "Paterson",
      "year": "2002"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib30",
      "doi-asserted-by": "crossref",
      "first-page": "105",
      "DOI": "10.1016/S0924-8579(01)00474-5",
      "article-title": "Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients",
      "volume": "19",
      "author": "Kitzes-Cohen",
      "year": "2002",
      "journal-title": "Int J Antimicrob Agents"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib31",
      "series-title": "Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy",
      "first-page": "2",
      "article-title": "Evaluation of pharmacodynamic target attainment between healthy subject and patient data using Monte Carlo simulation",
      "author": "Kuti",
      "year": "2003"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib32",
      "doi-asserted-by": "crossref",
      "first-page": "565",
      "DOI": "10.1093/ajhp/60.6.565",
      "article-title": "Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts",
      "volume": "60",
      "author": "Kuti",
      "year": "2003",
      "journal-title": "Am J Health Syst Pharm"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib33",
      "doi-asserted-by": "crossref",
      "first-page": "1264",
      "DOI": "10.1093/ajhp/61.12.1264",
      "article-title": "Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts in a large teaching hospital",
      "volume": "61",
      "author": "Kotapati",
      "year": "2004",
      "journal-title": "Am J Health Syst Pharm"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib34",
      "doi-asserted-by": "crossref",
      "first-page": "8",
      "DOI": "10.1592/phco.24.1.8.34804",
      "article-title": "Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae Acinetobacter baumannii, and Pseudomonas aeruginosa",
      "volume": "24",
      "author": "Kuti",
      "year": "2004",
      "journal-title": "Pharmacotherapy"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib35",
      "first-page": "24",
      "article-title": "The treatment of pulmonary infection in cystic fibrosis",
      "volume": "96",
      "author": "Webb",
      "year": "1995",
      "journal-title": "Scand J Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib36",
      "doi-asserted-by": "crossref",
      "first-page": "169",
      "DOI": "10.1007/BF02914541",
      "article-title": "Pharmacokinetics of drugs in cystic fibrosis",
      "volume": "9",
      "author": "Spino",
      "year": "1991",
      "journal-title": "Clin Rev Allergy"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib37",
      "doi-asserted-by": "crossref",
      "first-page": "873",
      "DOI": "10.1007/s100960050211",
      "article-title": "Pharmacokinetics of meropenem in patients with cystic fibrosis",
      "volume": "17",
      "author": "Christensson",
      "year": "1998",
      "journal-title": "Eur J Clin Microbiol Infect Dis"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib38",
      "doi-asserted-by": "crossref",
      "first-page": "153",
      "DOI": "10.1159/000063216",
      "article-title": "Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients",
      "volume": "47",
      "author": "Bui",
      "year": "2001",
      "journal-title": "Chemotherapy"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib39",
      "doi-asserted-by": "crossref",
      "first-page": "988",
      "DOI": "10.1592/phco.23.8.988.32878",
      "article-title": "Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion",
      "volume": "23",
      "author": "Dandekar",
      "year": "2003",
      "journal-title": "Pharmacotherapy"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib40",
      "doi-asserted-by": "crossref",
      "first-page": "518",
      "DOI": "10.1093/jac/dkg378",
      "article-title": "Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection",
      "volume": "52",
      "author": "Jaruratanasirikul",
      "year": "2003",
      "journal-title": "J Antimicrob Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib41",
      "series-title": "Program and Abstracts of the International Conference of the American Thoracic Society",
      "article-title": "Prevention of emergence of resistance in Pseudomonas aeruginosa infections through pharmacodynamic dosing and combination chemotherapy",
      "author": "Drusano",
      "year": "2002"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib42",
      "doi-asserted-by": "crossref",
      "first-page": "1116",
      "DOI": "10.1177/0091270003257225",
      "article-title": "Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem",
      "volume": "43",
      "author": "Kuti",
      "year": "2003",
      "journal-title": "J Clin Pharmacol"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib43",
      "unstructured": "Kuti JL, Moss KM, Nicolau DP, et al. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a cystic fibrosis patient by applying pharmacodynamic concepts to meropenem therapy. Pharmacotherapy. In press."
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib44",
      "doi-asserted-by": "crossref",
      "first-page": "608",
      "DOI": "10.1016/0002-9343(79)90242-0",
      "article-title": "A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients",
      "volume": "67",
      "author": "Bodey",
      "year": "1979",
      "journal-title": "Am J Med"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib45",
      "doi-asserted-by": "crossref",
      "first-page": "391",
      "DOI": "10.2165/00003088-199835050-00004",
      "article-title": "Continuous infusion of \u03b2-lactam antibiotics",
      "volume": "35",
      "author": "MacGowan",
      "year": "1998",
      "journal-title": "Clin Pharmacokinet"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib46",
      "doi-asserted-by": "crossref",
      "first-page": "471",
      "DOI": "10.1592/phco.22.7.471.33665",
      "article-title": "Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital",
      "volume": "22",
      "author": "Grant",
      "year": "2002",
      "journal-title": "Pharmacotherapy"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib47",
      "first-page": "156",
      "article-title": "Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride",
      "volume": "51",
      "author": "Walker",
      "year": "1998",
      "journal-title": "Can J Hosp Pharm"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib48",
      "doi-asserted-by": "crossref",
      "first-page": "412",
      "DOI": "10.1093/ajhp/54.4.412",
      "article-title": "Stability of meropenem in intravenous solutions",
      "volume": "54",
      "author": "Patel",
      "year": "1997",
      "journal-title": "Am J Health Syst Pharm"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib49",
      "doi-asserted-by": "crossref",
      "first-page": "992",
      "DOI": "10.1093/ajhp/57.10.992",
      "article-title": "Stability of meropenem in a portable infusion device in a cold pouch",
      "volume": "57",
      "author": "Grant",
      "year": "2000",
      "journal-title": "Am J Health Syst Pharm"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib50",
      "doi-asserted-by": "crossref",
      "first-page": "911",
      "DOI": "10.1093/jac/28.6.911",
      "article-title": "Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion",
      "volume": "28",
      "author": "Mouton",
      "year": "1991",
      "journal-title": "J Antimicrob Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib51",
      "doi-asserted-by": "crossref",
      "first-page": "523",
      "DOI": "10.1093/jac/43.4.523",
      "article-title": "Continuous infusion versus intermittent administration of meropenem in critically ill patients",
      "volume": "43",
      "author": "Thalhammer",
      "year": "1999",
      "journal-title": "J Antimicrob Chemother"
    },
    {
      "key": "10.1016/S0149-2918(04)80001-8_bib52",
      "doi-asserted-by": "crossref",
      "first-page": "493",
      "DOI": "10.1016/S0149-2918(04)90051-3",
      "article-title": "Pharmacokinetic properties and stability of continuousinfusion meropenem in adults with cystic fibrosis",
      "volume": "26",
      "author": "Kuti",
      "year": "2004",
      "journal-title": "Clin Ther"
    }
  ],
  "container-title": "Clinical Therapeutics",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://api.elsevier.com/content/article/PII:S0149291804800018?httpAccept=text/xml",
      "content-type": "text/xml",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://api.elsevier.com/content/article/PII:S0149291804800018?httpAccept=text/plain",
      "content-type": "text/plain",
      "content-version": "vor",
      "intended-application": "text-mining"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2023,
        4,
        29
      ]
    ],
    "date-time": "2023-04-29T15:31:10Z",
    "timestamp": 1682782270000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0149291804800018"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2004,
        8
      ]
    ]
  },
  "references-count": 52,
  "journal-issue": {
    "issue": "8",
    "published-print": {
      "date-parts": [
        [
          2004,
          8
        ]
      ]
    }
  },
  "alternative-id": [
    "S0149291804800018"
  ],
  "URL": "http://dx.doi.org/10.1016/S0149-2918(04)80001-8",
  "relation": {},
  "ISSN": [
    "0149-2918"
  ],
  "subject": [],
  "container-title-short": "Clinical Therapeutics",
  "published": {
    "date-parts": [
      [
        2004,
        8
      ]
    ]
  }
}